A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13
Meningococcal Serogroup B Vaccine
Infections, Meningococcal
Phase 3
This is an extension study of V72P13. An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register entry for this study.
October 2015